期刊文献+

药师在药物基因组学临床实践中的角色 被引量:1

The role of pharmacist in clinical pharmacogenomics
下载PDF
导出
摘要 药物基因组学的临床实践推动着精准医学的发展。笔者从一名药师的角度,分析药师在药物基因组学临床应用中的主导作用和具体职责,并从国外现阶段的应用实例中探讨药师所面临的挑战和相应对策,为药师今后开展相关服务和实践提供参考。 The clinical practice of pharmacogenomics promotes the development of precision medicine . From the perspec-tive of a pharmacist , the author analyzed the leading roles and specific responsibilities of pharmacists in pharmacogenomics , dis-cussed the challenges to incorporate pharmacogenomics into patient cares and provided reference for the domestic pharmacists to carry out pharmacogenomics services in the future .
作者 傅翔 李向荣 FU Xiang;LI Xiangrong(Department of Pharmacy , Kongjiang Hospital, Shanghai 200093 ,Chin)
机构地区 控江医院药剂科
出处 《药学实践杂志》 CAS 2017年第6期569-572,共4页 Journal of Pharmaceutical Practice
关键词 药物基因组学 药师 pharmacogenomics pharmacists
  • 相关文献

参考文献3

二级参考文献30

  • 1COTTON J M, WORRAL A M, HOBSON A R, et al. In- dividualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? [ J ]. Cardiovasc Ther, 2010, 28(3) :139-146.
  • 2TAUBERTD, VON BECKERATH N, GRIMBERG G, et al. Impact of P-glyeoprotein on elopidogrel absorption[ J ].Clin Pharmaeol Ther, 2006,80 ( 5 ) : 486- 501.
  • 3SIMON T ,VERSTUYFT C ,MARY-KRAUSE M ,et al.Gene- tie determinants of response to elopidogrel and cardiovascular events [ J ], N Engl J Med, 2009,360 (4) : 363-375.
  • 4CHEN L, QIN S, XIE J, et al.Genetie polymorphism analy- sis of CYP2C19 in. Chinese Han populations from different geographic areas of China's Mainland [ J]. Pharmacogenomics, 2008,9 (6) : 691-702.
  • 5ZHOU Q,YU X M, LIU H B,et al.Genetic polymorphism, linkage disequilibrium, haplotypestructure and novel allele analysis of CYP2C19 and CYP2D6 in" Han Chinese [ J ]. Pharmacogenomics, 2009,9(6) : 380-394.
  • 6MEGA J L, CLOSE S L, WIVIOTF S D, et al. Cytochrome P4s0 polymorphisms and response to clopidogrel[ J ]. N Engl J Med, 2009,360 (4) : 354- 362.
  • 7CHANM Y,TAN K,TANH C,et aI. CYP2C19 and PON1 polymorphisms regulating clopidogrelbioactivation in Chinese, Malay and Indian subjects [ J ]. Pharmaco- genomics, 2012,13 ( 5 ) : 533- 542.
  • 8BHATT D L,PARE G, EIKELBOOM J W,et al.The relati- onship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study [ J ]. Eur Heart J, 2012,33 ( 17 ) : 2143-2150.
  • 9GLADDING P, WEBSTER M, ZENG L, et al. The phar- macogenetics and pharmacodynamics of clopidogrel res- ponse: an analysis from the PRINC (plavix response in coronary intervention) trial [ J ]. JACC Cardiovasc Interv, 2008,1 (6) :620-627.
  • 10JEONG Y H, LEE W, CHOI B R, et al.Randomized com- parison of adjunctive cilostazol versus high main-tenance dose clopidogrel in patients with high post-treatment plateletreactivity: results of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance ) randomized study[ J ]. J Am Coil Cardiol, 2009, 53 ( 13 ) : 1101-1109.

共引文献5

同被引文献14

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部